Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

2.50EUR
8:27am GMT
Change (% chg)

€0.20 (+8.70%)
Prev Close
€2.30
Open
€2.39
Day's High
€2.51
Day's Low
€2.38
Volume
446,401
Avg. Vol
707,470
52-wk High
€4.26
52-wk Low
€2.04

Select another date:

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue

* PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE) Source text for Eikon:

BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma

* PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA

BRIEF-Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment

* SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY

BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA

BRIEF-Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY

* 9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO

BRIEF-Pharma Mar presents updated data from Zepsyre Phase I/II trials in SCLC‍​

* PROGRESSION FREE SURVIVAL BENEFIT OBSERVED IN COMBINATION OF PM1183 AND DOXORUBICIN IN SMALL-CELL LUNG CANCER (SCLC)

BRIEF-Pharma Mar submits MAA for Aplidin in Switzerland for multiple myeloma treatment

* SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) FOR APLIDIN IN SWITZERLAND FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA‍​ Source text: http://bit.ly/2xf24h3

BRIEF-Pharma Mar starts clinical studies with new compound PM14 in patients with solid tumors

* SAYS STARTS CLINICAL STUDIES WITH NEW COMPOUND PM14 IN PATIENTS WITH SOLID TUMORS Source text for Eikon:

BRIEF-Pharma Mar presents response rate data with PM1183 in patients with lung cancer‍​

* NEW POSITIVE DATA ON PM1183 SEES RESPONSE RATE OF 36 PERCENT AS SINGLE AGENT IN PATIENTS WITH ADVANCED AND RELAPSED SMALL-CELL LUNG CANCER

Select another date: